27 August 2026 in Indian Journal of Otolaryngology and Head & Neck Surgery
ITInés Tortajada-Torralba
ACAlexandra Cortés-Arciniegas
Alexandra Cortés-Arciniegas
MAMiguel Armengot-Carceller
Miguel Armengot-Carceller
9 June 2025 in Indian Journal of Otolaryngology and Head & Neck Surgery
AVAgustín Alamar Velázquez
MCMiguel Armengot Carceller
Miguel Armengot Carceller
15 July 2025 in Acta Otorrinolaringologica (English Edition)
CPCarlos de Paula-Vernetta
1 August 2025 in Otology & Neurotology
ACAna Belén Castilla-Jiménez
Ana Belén Castilla-Jiménez
Objective: To assess the potential of eslicarbazepine as an effective and tolerable treatment for vestibular paroxysmia compared to standard drugs. Patients: A cohort of five patients fulfilling criteria of probable or definite vestibular paroxysmia were included in the study. Intervention: Patients were treated with eslicarbazepine in daily regime with an initial dose of 400 mg. Main Outcome Measure: Reduction in number of crises of vestibular paroxysmia per week was measured according to patients’ self-report, to evaluate clinical efficacy. Results: Mean treatment period was 10.6 months. Mean follow-up period was 21 months. Four of the five patients treated with eslicarbazepine achieved a total response with one of the five patients having a partial response with a mean reduction of 70% in the number of crises. The response to the withdrawal of the drug was highly variable in each patient. The most common adverse effects identified in the cohort were nausea, vomiting, and mild biochemical abnormalities. Two of the five patients experienced stochastic effects, which motivated drug removal. Conclusion: Eslicarbazepine shows good preliminary results achieving symptomatic relief in patients diagnosed with vestibular paroxysmia. Its enhanced safety profile with less adverse effects and drug interactions with respect to standard therapies could facilitate therapeutical adherence without detriment of its efficacy.
21 September 2026 in The Journal of International Advanced Otology
Blue laser technology, specifically the 445-450 nm wavelength blue diode laser, represents an emerging innovation in otologic surgery with unique photoangiolytic and hemostatic properties. This narrative review discusses evidence from otologic studies directly addressing the 445-450 nm blue diode laser to evaluate the clinical applications, outcomes, and safety profile of blue laser systems in ear surgery. The technology hasbeen explored in stapedotomy procedures for otosclerosis, middle ear paraganglioma excision, and cholesteatoma surgery. Preliminary and still limited clinical data suggest audiological outcomes broadly comparable to traditional carbon dioxide laser systems, with a proposed advantage in hemostasis and thermal. Direct otologic evidence remains limited to a small number of case series and retrospective comparisons, with most publications emerging between 2018 and 2025. This review identifies blue laser technology as a promising adjunct to the otologic surgeon’s armamentarium, warranting larger randomized controlled trials to establish definitive clinical guidelines and long-term safety profiles.